<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768846</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S03008</org_study_id>
    <nct_id>NCT00768846</nct_id>
  </id_info>
  <brief_title>Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World</brief_title>
  <acronym>ZEPPELIN</acronym>
  <official_title>Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The zotarolimus-eluting Endeavor Resolute stent is not inferior to the everolimus- eluting
      Xience V stent platform regarding a composite of cardiac death, myocardial infarction or
      target lesion revascularisation in a real-world population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of stents has become common practice in the percutaneous treatment of coronary artery
      disease. Restenosis affected 20-40% of de novo coronary lesions treated with bare metal
      stents. Drug-eluting stents (DES) have emerged as the most effective strategy for the
      prevention of restenosis. The first available DES were the Sirolimus-eluting Cypher and the
      Paclitaxel-eluting Taxus stent. Although their mid-term efficacy has been well-established,
      there is an ongoing debate on the potential of an increased incidence of late stent
      thrombosis, as well as of delayed onset of restenosis or catch-up phenomenon with DES. Recent
      evidence demonstrates that there might be differences between various DES in terms of safety
      and efficacy. The differences might be related to the drug, polymer or stent design.
      Everolimus (SDZ-RAD) and zotarolimus (ABT-578) are new antiproliferative agents that share
      some common structural and biological properties with sirolimus (&quot;limus-group&quot;). Both drugs
      bind to the intracellular sirolimus receptor, FK 506-binding protein 12 (FKBP 12). The
      drug-FKBP12 complex inhibits cell cycle progression via inactivation of the mammalian target
      of Rapamycin (mTOR) thereby regulating vascular smooth muscle cell migration and
      proliferation. Preclinical studies showed improved endothelialization and limited chronic
      inflammation of the everolimus-eluting stent compared with previous drug-eluting stents.
      Moreover, first randomized clinical trials of everolimus-eluting stents have shown promising
      results regarding safety, feasibility and efficacy in the suppression of neointimal
      proliferation. Safety and efficacy of the zotarolimus-eluting Endeavor stent have been
      investigated in the Endeavor clinical program. In the Endeavor III and IV trials, the
      Endeavour stent proved inferior to the Cypher and Taxus stents regarding angiographic
      endpoints. However, rates of target vessel failure were similar in both groups. The Endeavor
      RESOLUTE stent platform uses a new polymer with potential improvements of drug release
      compared to the Endeavor stent. The RESOLUTE clinical trial is the first-in man,
      observational, uncontrolled, non-randomized study evaluating the Endeavor Resolute
      drug-eluting stent with the new polymer. The trial enrolled a total of 130 patients with
      native coronary artery lesions. There are no data available comparing the zotarolimus-eluting
      Endeavor Resolute stent with the everolimus-eluting Xience V stent. Thus the aim of this
      prospective, randomized study is to compare the efficacy and safety of these two &quot;new
      generation&quot; drug-eluting stent platforms in a real world population.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation</measure>
    <time_frame>1 year after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary angiographic restenosis</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor Resolute Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xience V Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor Resolute Stent</intervention_name>
    <description>Zotarolimus-eluting Endeavor Resolute Stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V Stent</intervention_name>
    <description>Everolimus-eluting Xience V Stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years with symptomatic coronary artery disease undergoing PCI
             with stent implantation.

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

        Exclusion Criteria:

          -  Cardiogenic shock.

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: everolimus, zotarolimus, cobalt chrome.

          -  Inability to take clopidogrel for at least 6 months.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test. (In women with
             childbearing potential a pregnancy test is mandatory.)

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julinda Mehilli, MD</last_name>
    <phone>+49-1218</phone>
    <phone_ext>4582</phone_ext>
    <email>mehilli@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Schulz, MD</last_name>
    <phone>+49-1218</phone>
    <phone_ext>1521</phone_ext>
    <email>schulzs@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1st Medizinische Klinik Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Dirschinger, MD</last_name>
      <phone>+49-4140</phone>
      <phone_ext>2947</phone_ext>
      <email>dirschinger@med1.med.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julinda Mehilli, MD</last_name>
      <phone>+49-1218-</phone>
      <phone_ext>4582</phone_ext>
      <email>mehilli@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Schulz, MD</last_name>
      <phone>+49-1218-</phone>
      <phone_ext>1521</phone_ext>
      <email>schulzs@dhm.mhn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>October 11, 2008</last_update_submitted>
  <last_update_submitted_qc>October 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. A. Schoemig</name_title>
    <organization>Klinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Muenchen</organization>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Stent</keyword>
  <keyword>DES</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

